Chembio Receives $2.9M SBIR Grant to Develop Antibody-Based Tuberculosis Test
March 04, 2011
Chembio Receives $2.9M SBIR Grant to Develop Antibody-Based Tuberculosis Test
The test, which the company says showed sensitivity of 81 percent and specificity of 95 percent in pilot studies, uses a panel of polyepitope fusion proteins based on antigens involved in the antibody response to pulmonary tuberculosis.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- NCI Kicks Off Second Stage of Clinical Proteomic Technologies for Cancer Initiative
August 26, 2011 / ProteoMonitor - Yale-Led Group Links Protein Markers to Kidney Injury in Cardiac Surgery Patients
August 26, 2011 / ProteoMonitor - NextGen Inks Deal with University of Nebraska to Use Biomarker Discovery Panel for NeuroAIDS Work
August 19, 2011 / ProteoMonitor - Macquarie Begins Coverage of Danaher
August 18, 2011 / GenomeWeb Daily News - Nottingham Group Wins $1.1M for Alzheimer's Protein Biomarker Research
August 12, 2011 / ProteoMonitor